GlassScriptPhysician profile
Kaveh Samani
NPI 1720118458
$8,854.02
in general payments reported to CMS, 2019-2025
31 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $1,545 · 2021: $1,580 · 2022: $1,401 · 2023: $1,670 · 2024: $1,725 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,784.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,792.24 | 2019-2024 | Gallant, Unify Assura, Accent |
| Astrazeneca Pharmaceuticals LP | $415.90 | 2021-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.04 | 2019-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $224.38 | 2021-2023 | Krystexxa |
| Amgen INC. | $221.02 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $213.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $194.04 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ardelyx, INC. | $170.56 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $120.23 | 2021-2023 | Veltassa |
| Astellas Pharma US INC | $117.31 | 2020-2023 | Veozah |
| Novo Nordisk INC | $99.33 | 2024-2025 | Rybelsus, Ozempic |
| Cardiovascular Systems INC. | $90.74 | 2019 | |
| Lilly USA, LLC | $78.60 | 2024 | Mounjaro |
| Pfizer INC. | $76.88 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $73.11 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.58 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $64.99 | 2024-2025 | |
| Exact Sciences Corporation | $54.53 | 2023-2024 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $37.58 | 2021-2023 | Gimoti |
| Scilex Pharmaceuticals INC. | $37.28 | 2019-2020 | |
| Medtronic, INC. | $36.20 | 2025 | Minimed 780g |
| Scpharmaceuticals INC. | $34.89 | 2024 | |
| Genzyme Corporation | $28.66 | 2023 | |
| Calliditas Therapeutics US INC. | $27.29 | 2022 | |
| Mylan Specialty L.P. | $25.71 | 2022 | |
| Aurinia Pharma U.S., INC. | $25.05 | 2022 | |
| Akebia Therapeutics INC | $23.02 | 2025 | Vafseo |
| Paratek Pharmaceuticals, INC. | $17.52 | 2023 | Nuzyra |
| Abbvie INC. | $16.30 | 2024 | |
| Amarin Pharma, INC. | $13.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaveh Samani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.